The independent medical news service

Click through for the details of this FDA decision

Find out more details here

The Taiwan Lung Cancer Screening in Never-Smoker Trial suggests that low-dose computed tomography screening may help to detect early-stage disease in never smokers at high risk for developing lung cancer.

Non-small-cell lung cancer survival after complete resection was not improved by use of mRNA expression levels of two genes to guide choice of adjuvant chemotherapy, shows research reported at the IASLC 2020 World Conference on Lung Cancer.

Read more about this US FDA decision here

Promising early data on several novel treatment options for non-small-cell lung cancer harboring rare EGFR alterations have been reported at the IASLC 2020 World Conference on Lung Cancer.

AMG 757, a half-life extended, bispecific T-cell engager immunotherapy directed against DLL3, has demonstrated tolerability and antitumor activity in patients with previously treated small-cell lung cancer in a phase 1 trial.

Two cycles of neoadjuvant atezolizumab may benefit patients with resectable non-small-cell lung cancer, indicate findings from the LCMC3 study presented at the IASLC 2020 World Conference on Lung Cancer.

Health-related quality of life is maintained during long-term treatment with adjuvant osimertinib in people with resected, EGFR-mutated non-small-cell lung cancer, research shows.

Three early-phase studies presented at the IASLC 2020 World Conference on Lung Cancer point to the potential of antibody–drug conjugates for the treatment of different populations of patients with advanced non-small-cell lung cancer.

Two independent studies presented at the IASLC 2020 World Conference on Lung Cancer have highlighted the heightened psychological distress experienced by patients with cancer – especially those with lung cancer – during the COVID-19 pandemic.

Adding ipilimumab to pembrolizumab does not boost the efficacy of the PD-1 inhibitor in untreated patients with metastatic non-small-cell lung cancer and high PD-L1 expression, but leads to worse toxicity, shows the KEYNOTE-598 trial.

The oral selective AXL inhibitor bemcentinib is well-tolerated and clinically active when combined with pembrolizumab to treat immunotherapy-naïve or refractory advanced non-small-cell lung cancer, phase 2 study data show.

The KRAS inhibitor sotorasib achieves clinical benefit in individuals who have received prior treatment for advanced non-small-cell lung cancer harboring a KRAS G12C mutation, suggest data from the phase 2 cohort of CodeBreaK 100.

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

Adding bevacizumab to osimertinib therapy does not improve progression-free survival for patients with advanced non-small-cell lung cancer harboring an EGFR T790M mutation, phase 2 study data suggest.

Interim analysis of the CameL trial indicates that progression-free survival for Chinese patients with advanced nonsquamous non-small-cell lung cancer is improved with the first-line use of the PD-1 inhibitor camrelizumab alongside chemotherapy.

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

A review of data from the osimertinib clinical trials program has not identified a causal relationship between the use of the EGFR–tyrosine kinase inhibitor and cardiotoxicity among patients with advanced non-small-cell lung cancer.